Biotech news
Biotech
New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4. 5 August 2014
Americas
Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million. 31 July 2014
Americas
US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind. 29 July 2014
Biotech
German medical device company Occlutech has successfully defeated US-based AGA Medical Corporation after the English High Court declared a patent AGA was trying to assert invalid. 25 July 2014
Biotech
The Attorney General for the Court of Justice of the European Union has issued an opinion on the meaning of the term ‘human embryos’ that could "significantly restrict" the scope of the Brüstle decision of 2011. 21 July 2014
Asia
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world. 8 July 2014
Biotech
The EPO generally accepts applications relating to human embryonic stem cells with an effective date after 2008 but discussions about eligibility continue, says Joachim Wachenfeld. 7 July 2014
Americas
Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion. 2 July 2014
Asia
IP legislation in the United Arab Emirates is among the strongest in the region but the courts have had so few issues to handle that the country’s lawyers and judges may not yet be well equipped to deal with biotech cases. 27 June 2014
Americas
Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday. 26 June 2014